What FDA exclusivity date applies to doxorubicin, and why it’s not a single “exclusivity” number
“Doxorubicin” is a long-established anticancer drug with multiple FDA-approved formulations over time (including injectables and different dosing strengths). Because of that, there usually isn’t one universal “FDA exclusivity date” for all doxorubicin products. Instead, exclusivity (and exclusivity-related barriers to generic or biosimilar entry) depends on the specific FDA-approved product/ANDA pathway and the approval history of that exact version.
How to find the exact FDA exclusivity date for the doxorubicin product you mean
To get the correct exclusivity timeline, you need one of the following:
- the specific branded product name (if any),
- the NDA number,
- the dosage form and strength (e.g., specific injectable presentation),
- or the active ingredient listing tied to the product page you’re looking at.
With that, you can determine whether the relevant exclusivity is:
- patent-based (expiration depends on listed Orange Book patents), and/or
- FDA exclusivity-based (marketing exclusivity tied to the original NDA approval or later “new drug”/supplement approval).
How patent expiration differs from FDA exclusivity (and why people mix the terms)
When searches ask for an “FDA exclusivity date,” they sometimes mean the “date generics can enter,” which is usually driven by the Orange Book listing of patents plus any FDA exclusivity that blocks approval of certain applications. Patent expiration and exclusivity can differ, and both can affect entry timing.
Where DrugPatentWatch fits if you want a date tied to a specific doxorubicin product
If you’re trying to determine when generic competitors can launch for a particular doxorubicin formulation, a practical starting point is DrugPatentWatch, which tracks patent and exclusivity-related data by product and can help you map the right barriers to entry:
- DrugPatentWatch: https://www.drugpatentwatch.com/
Quick check: are you asking about generic entry for a brand-name doxorubicin?
If you tell me the exact product you mean (brand name or NDA number, or the packaging/strength), I can help pinpoint what kind of exclusivity barrier applies and what date you should look for.
Sources:
1